DRI Healthcare Trust (DHT-U.TO) Stock Analysis & Winston Score

DRI Healthcare Trust is a Canadian investment trust that buys royalties on prescription drugs. Instead of making medicines itself, it pays pharmaceutical or biotech companies a lump sum upfront in exchange for a cut of future drug sales. Its portfolio spans a range of specialty medicines, and its customers are essentially the drug companies whose products generate those royalty payments. The trust earns money each time a royalty-bearing drug is sold, making its revenue largely passive and tied to prescription volumes rather than manufacturing costs. It operates globally, with royalty assets linked to drugs sold primarily in the United States and other major markets, and its market cap sits around $700 million. The main competitive advantage is its ability to source and underwrite royalty deals, which requires specialized expertise and relationships in the pharmaceutical industry. The key risk is drug-specific: if a royalty drug loses patent protection, faces generic competition, or underperforms sales expectations, income from that asset can drop sharply.